Literature DB >> 12967632

Evidence for rapid "metabolic switching" through lipoprotein lipase occupation of endothelial-binding sites.

Thomas Pulinilkunnil1, Ashraf Abrahani, Jospy Varghese, Nathan Chan, Irvin Tang, Sanjoy Ghosh, Jerze Kulpa, Michael Allard, Roger Brownsey, Brian Rodrigues.   

Abstract

During diabetes, impaired glucose transport and utilization by the heart switches energy production to exclusive beta-oxidation of fatty acid (FA). In the current study, we examined the contribution of cardiac lipoprotein lipase (LPL) towards providing FA to the diabetic heart. Streptozotocin (STZ) caused an augmentation of LPL activity at the coronary lumen, an effect duplicated by diazoxide (DZ). With DZ, the amplification of LPL at the coronary luminal surface was determined to be exceptionally rapid. Interestingly, unlike DZ, the capability of hearts from STZ animals to maintain this amplified LPL activity was sustained in vitro. This increased enzyme in the hyperglycemic heart is likely unrelated to an increase in the number of capillary endothelial LPL-binding sites. Our data imply that binding sites for LPL in the control rat heart are only partly occupied by the enzyme and diabetes rapidly initiates filling of all of these sites. Phloridzin treatment of STZ animals normalized plasma glucose with no effect on luminal LPL suggesting that the effects of diabetes on LPL are also largely independent of changes in blood glucose. Both 2 and 8 U of insulin normalized plasma glucose in DZ-treated animals but only 8 U reversed DZ-induced augmentation of cardiac luminal LPL. Our data suggest that impaired intracellular glucose utilization allows rapid vectorial transfer of LPL to unoccupied binding sites to supply the diabetic heart with excess FA. The persistence of increased coronary luminal LPL even in a setting of normoglycemia may provide excessive FA to the diabetic heart with deleterious consequences over the long term.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967632     DOI: 10.1016/s0022-2828(03)00205-0

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Authors:  Vijay Sharma; John H McNeill
Journal:  World J Cardiol       Date:  2011-09-26

Review 2.  New wrinkles in lipoprotein lipase biology.

Authors:  Brandon S J Davies; Anne P Beigneux; Loren G Fong; Stephen G Young
Journal:  Curr Opin Lipidol       Date:  2012-02       Impact factor: 4.776

3.  Chylomicron metabolism in rats: kinetic modeling indicates that the particles remain at endothelial sites for minutes.

Authors:  Magnus Hultin; Roger Savonen; Olivier Chevreuil; Thomas Olivecrona
Journal:  J Lipid Res       Date:  2013-08-06       Impact factor: 5.922

Review 4.  Cardiac lipotoxicity: molecular pathways and therapeutic implications.

Authors:  Konstantinos Drosatos; P Christian Schulze
Journal:  Curr Heart Fail Rep       Date:  2013-06

Review 5.  Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy.

Authors:  Andrea Wan; Brian Rodrigues
Journal:  Cardiovasc Res       Date:  2016-06-10       Impact factor: 10.787

6.  Does long-term metformin treatment increase cardiac lipoprotein lipase?

Authors:  David Hauton
Journal:  Metabolism       Date:  2010-02-12       Impact factor: 8.694

7.  Cleavage of protein kinase D after acute hypoinsulinemia prevents excessive lipoprotein lipase-mediated cardiac triglyceride accumulation.

Authors:  Min Suk Kim; Fang Wang; Prasanth Puthanveetil; Girish Kewalramani; Sheila Innis; Lucy Marzban; Susan F Steinberg; Travis D Webber; Timothy J Kieffer; Ashraf Abrahani; Brian Rodrigues
Journal:  Diabetes       Date:  2009-11       Impact factor: 9.461

8.  Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy.

Authors:  Thomas Pulinilkunnil; Petra C Kienesberger; Jeevan Nagendran; Terri J Waller; Martin E Young; Erin E Kershaw; Gregory Korbutt; Guenter Haemmerle; Rudolf Zechner; Jason R B Dyck
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.